Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.69 |
| ▸ | TP53 | P04637 | 1/20 | 0.69 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.69 |
| ▸ | CA12 | O43570 | 2/20 | 0.69 |
| ▸ | CA9 | Q16790 | 1/20 | 0.69 |
| ▸ | NPC1 | O15118 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.57 |
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30546567 | 1.00 | GSK3B (0.75) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| Methane SCHEMBL11813940 | 0.98 | GSK3B (0.73) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL1906596 | 0.87 | GSK3B (0.73) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL694554 | 0.86 | GSK3B (0.71) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL696173 | 0.86 | GSK3B (0.71) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL14711680 | 0.86 | GSK3B (1.00) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL10671594 | 0.84 | CA12 (0.59) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL29236638 | 0.83 | GSK3B (0.68) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL401800 | 0.82 | GSK3B (0.57) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 | |
| SCHEMBL1609678 | 0.82 | SMN1; SMN2 (0.62) | GSK3BSMN1; SMN2KDM4ETP53L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 123 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4707276-A2 | MALT1 MODULATORS AND USES THEREOF | Rarefied Biosciences, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| EP-4499611-B1 | MALT1 MODULATORS AND USES THEREOF | RAREFIED BIOSCIENCES INC (US) | 2026-02-18 | — | — | EP | disclosed |
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | RAREFIED BIOSCIENCES, INC. (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3891158-B1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2025-09-10 | — | — | EP | disclosed |
| US-12247045-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2025-03-11 | — | — | US | disclosed |
| US-20240199621-A1 | MAP4K4 INHIBITORS | IMPERIAL COLLEGE INNOVATIONS LTD (GB) | 2024-06-20 | — | — | US | disclosed |
| CN-118184477-A | Method for preparing chiral amino alcohol compound by catalyzing amino ketone with nickel metal by using water as hydrogen source | 云南民族大学 | 2024-06-14 | — | — | CN | disclosed |
| CN-112585147-B | MAP4K4 inhibitors | 帝国理工学院创新有限公司 | 2023-12-05 | — | — | CN | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| US-11795169-B2 | MAP4K4 inhibitors | IMPERIAL COLLEGE INNOVATIONS LIMITED (GB) | 2023-10-24 | — | — | US | disclosed |
| EP-0061178-B1 | NOVEL 1,2-DIHYDROPYRIDO(3,4-B)-PYRAZINES AND METHOD FOR PREPARING SAME | Southern Research Institute (US) | 1986-02-26 | — | — | EP | disclosed |
| EP-0172147-A2 | Amide derivatives of 2-(p-aminobenzyl)-butyric acid and esters thereof having hypolipidemizing activity | Medosan Industrie Biochimiche Riunite S.r.l. (IT) | 1986-02-19 | — | — | EP | disclosed |
| EP-0151765-A2 | Novel intermediates in a process for making novel 1,2-dihydropyrido(3,4-b)-pyrazines | Southern Research Institute (US) | 1985-08-21 | — | — | EP | disclosed |
| US-4511721-A | Intermediate for preparing antifungal 1,2-dihydropyrido[3,4-b]-pyrazines | SOUTHERN RESEARCH INSTITUTE (US) | 1985-04-16 | — | — | US | disclosed |
| US-4453003-A | ENZYME INHIBITORS, ANTIINFLAMMATORY AGENTS | UMEZAWA HAMAO (JP) | 1984-06-05 | — | — | US | disclosed |
| US-4450160-A | ANTIDEPRESSANTS | SOUTHERN RESEARCH INSTITUTE (US) | 1984-05-22 | — | — | US | disclosed |
| US-4410618-A | DEVELOPMENT INHIBITORS | EASTMAN KODAK COMPANY (US) | 1983-10-18 | — | — | US | disclosed |
| US-4391986-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediates therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1983-07-05 | — | — | US | disclosed |
| EP-0061178-A2 | Novel 1,2-dihydropyrido(3,4-b)-pyrazines and method for preparing same | Southern Research Institute (US) | 1982-09-29 | — | — | EP | disclosed |
| US-4281180-A | Process for producing threo-3-amino-2-hydroxybutanoyl-aminoacetic acids, as well as novel intermediated therefor and process for producing them | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250326738-A1 | MALT1 Modulators and Uses Thereof | MALT1, SQSTM1, PPP1R10 | GSK3B 534/4885SMN1; SMN2 2034/4885KDM4E 2044/4885 |
| US-12247045-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K5, MAP4K1 | GSK3B 300/4885SMN1; SMN2 2995/4885KDM4E 1003/4885 |
| US-11795169-B2 | MAP4K4 inhibitors | MAP4K4, MAP4K2, MAP4K5 | GSK3B 493/4885SMN1; SMN2 3315/4885KDM4E 742/4885 |
| US-20240199621-A1 | MAP4K4 INHIBITORS | MAP4K4, MAP4K2, MAP4K5 | GSK3B 493/4885SMN1; SMN2 3315/4885KDM4E 742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.